UV Flu Technologies Announces European Market Penetration Opportunity for UV-400 Bacteria Killing Air Purifier

SOURCE: UV Flu Technologies, Inc.

CENTERVILLE, MA–(Marketwire – July 20, 2010) – UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is pleased to announce the receipt of an initial sales order via a European distributor for immediate delivery of 50 ViraTech UV-400 air purifiers to Societe Nema Citizen of Paris, France.

Societe Nema Citizen (www.citizenfrance.com) is the largest distributor of Citizen Brand electronics in France, along with a growing inventory of health and medical-related products readily sold throughout much of Western Europe. The Company is well established and offers an aggressive strategy designed to introduce the UV-400 to an existing audience base utilizing regional relationships and proven market penetration practices. 

“We expect this order to translate into dramatically larger shipments beginning in the 4th quarter,” stated Jack Lennon, President of UV Flu Technologies. “Our initial shipment is slated for use as demonstration units specifically targeting fifty catalog re-sellers. The distributor further supports these introductory efforts by providing a strong internet presence combined with a sizeable and knowledgeable sales force spread across the continent.

“The demographic makeup and densely populated urban environment of Europe complements the initial thrust of our marketing approach in a very profound manner. We have analyzed the marketplace and based on our findings we are determined to start by creating awareness within the aging populations where respiratory problems are a real issue. The ViraTech UV-400, which kills airborne bacteria, is a perfect fit for dramatically reducing the causes of many of these respiratory problems, and we aim to get the word out about our product as quickly and effectively as possible,” said Mr. Lennon.

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
Email Contact

Click here to see all recent news from this company

Leave a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll to Top